Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

3948 - A serum microRNA expression signature for radiosensitivity of non-small cell lung cancer

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Liyuan Fan

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

L. Fan1, B. Li2

Author affiliations

  • 1 Radiation Department, Shandong Provincial Western Hospital, 250022 - Ji'nan/CN
  • 2 Radiation Department, Shandong cancer hospital affiliated to Shandong university, Jinan/CN
More

Resources

Abstract 3948

Background

Chemoradiotherapy represents the main treatment for non-small cell lung cancer (NSCLC), especially for the advanced lung cancer. However, the curative effect varies significantly. Many microRNAs are verified to be associated with it and microRNA signature may be a good biomarker to predict the radiosensitivity.

Methods

Genome-wide microRNA profiling was analyzed by microarray and validated by qRT-PCR in radio-resistant cell lines and their parent cell lines (A549 and PC9, the corresponding cell lines named A549-R and PC9-R). Then we used colony formation by transfecting miRNA-mimics into A549 and PC9 for functional verification. Finally, a potential microRNA signature was established by an independent set of non-small cell lung cancer (NSCLC) serum samples and validated by available corresponding formalin-fixed paraffin-embedded tissue (FFPE) samples.

Results

73 up-regulated and 24 down-regulated miRNAs were found by microarray and 11 up-regulated, 3 down-regulated and 3 non-different miRNAs were rechecked by qRT-PCR. A miRNA signature, including miR-1290, miR-2861, miR-25-5p and miR-92a-1-5p was selected for further exploration. Overexpression of miR-1290 and miR-2861 increased the radio resistance of A549 and PC9 while overexpression of miR-25-5p and miR-92a-1-5p reversed the radio resistance of A549-R and PC9-R. The four-miRNAs signature could predict the chemotherapeutic response with high accuracy, 83.4% and 79.5% in both the test (serum samples) and validation (FFPE samples) cohorts respectively.

Conclusions

It is the first report of a miRNA signature for cell lines, serum and tissues. Serum and tissue miRNAs represent novel biomarkers to predict radiotherapy response clinically and may represent potential molecular targets to sensitize resistant cancers.

Clinical trial identification

Legal entity responsible for the study

Shandong Cancer Hospital affiliated to Shandong University.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.